GILD vs. UTHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GILD and UTHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | GILD | UTHR |
|---|---|---|
| Company Name | Gilead Sciences, Inc. | United Therapeutics Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 139.83 billion USD | 20.49 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | January 22, 1992 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of GILD and UTHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GILD | UTHR |
|---|---|---|
| 5-Day Price Return | 0.06% | 6.78% |
| 13-Week Price Return | 0.84% | 53.85% |
| 26-Week Price Return | 0.57% | 46.97% |
| 52-Week Price Return | 32.98% | 28.54% |
| Month-to-Date Return | 1.52% | 8.08% |
| Year-to-Date Return | 22.00% | 28.41% |
| 10-Day Avg. Volume | 8.25M | 0.93M |
| 3-Month Avg. Volume | 7.15M | 0.75M |
| 3-Month Volatility | 28.38% | 72.72% |
| Beta | 0.33 | 0.87 |
Profitability
Return on Equity (TTM)
GILD
32.97%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 32.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
UTHR
18.73%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, UTHR’s Return on Equity of 18.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GILD
21.87%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 21.87% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
UTHR
40.36%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 40.36% places UTHR in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
GILD
27.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 27.89% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
UTHR
47.05%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 47.05% places UTHR in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | GILD | UTHR |
|---|---|---|
| Return on Equity (TTM) | 32.97% | 18.73% |
| Return on Assets (TTM) | 11.19% | 16.48% |
| Net Profit Margin (TTM) | 21.87% | 40.36% |
| Operating Profit Margin (TTM) | 27.89% | 47.05% |
| Gross Profit Margin (TTM) | 78.53% | 88.98% |
Financial Strength
Current Ratio (MRQ)
GILD
1.32
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
GILD’s Current Ratio of 1.32 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
UTHR
7.26
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
UTHR’s Current Ratio of 7.26 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GILD
1.27
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
UTHR
0.00
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
UTHR’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
GILD’s Interest Coverage Ratio of 1.71 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
UTHR
42.15
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
UTHR’s Interest Coverage Ratio of 42.15 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | GILD | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 7.26 |
| Quick Ratio (MRQ) | 0.89 | 6.94 |
| Debt-to-Equity Ratio (MRQ) | 1.27 | 0.00 |
| Interest Coverage Ratio (TTM) | 1.71 | 42.15 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GILD
4.27%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 4.27% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
GILD
117.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 117.08%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | GILD | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 4.27% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.08% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
GILD
21.98
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
GILD’s P/E Ratio of 21.98 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UTHR
16.28
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
UTHR’s P/E Ratio of 16.28 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GILD
4.81
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
GILD’s P/S Ratio of 4.81 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
UTHR
6.57
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
UTHR’s P/S Ratio of 6.57 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
GILD
7.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
GILD’s P/B Ratio of 7.01 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UTHR
1.81
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
UTHR’s P/B Ratio of 1.81 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | GILD | UTHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.98 | 16.28 |
| Price-to-Sales Ratio (TTM) | 4.81 | 6.57 |
| Price-to-Book Ratio (MRQ) | 7.01 | 1.81 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.19 | 18.88 |